Description: Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of NSCLC, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. The company was incorporated in 2018 and is headquartered in San Diego, California.
Home Page: www.erasca.com
ERAS Technical Analysis
10835 Road to the Cure
San Diego,
CA
92121
United States
Phone:
858 465 6511
Officers
| Name | Title |
|---|---|
| Dr. Jonathan E. Lim M.D. | Co-Founder, Chairman & CEO |
| Mr. Ebun S. Garner J.D., Esq. | Gen. Counsel & Corp. Sec. |
| Dr. Wei Lin M.D. | Chief Medical Officer |
| Dr. Michael D. Varney Ph.D. | Chairman of R&D, Scientific Advisory Board Member and Director |
| Dr. David M. Chacko M.D. | Chief Financial Officer |
| Dr. Nik Chetwyn Ph.D. | Sr. VP of Operations |
| Dr. Lisa Tesvich-Bonora Ph.D. | Chief People Officer |
| Mr. Brian L. Baker CPA, M.S., MS, CPA | Sr. VP of Fin. |
| Ms. Chandra D. Lovejoy | Sr. VP of Regulatory Affairs |
| Dr. Robert Shoemaker Ph.D. | Sr. VP of Research |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.9025 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2021-07-16 |
| Fiscal Year End: | December |
| Full Time Employees: | 123 |